Health and Fitness Health and Fitness
Tue, December 14, 2010
[ Tue, Dec 14th 2010 ] - Market Wire
Acrongenomics Signs a Memorandum of Understanding .. Acquire the Majority Share of Cardioexpress Inc.
[ Tue, Dec 14th 2010 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Launches an .. ble Breaches of Fiduciary Duty by the Board of Ma
[ Tue, Dec 14th 2010 ] - Market Wire
Emergency Medical Services Confirms Review of Strategic Alternatives
[ Tue, Dec 14th 2010 ] - Market Wire
Synergetics USA Introduces Next Generation Electrosurgical Generator
[ Tue, Dec 14th 2010 ] - Market Wire
Bard Provides Financial Guidance for 2011
[ Tue, Dec 14th 2010 ] - Market Wire
Lannett Announces Pricing of Public Offering of Common Stock
[ Tue, Dec 14th 2010 ] - Market Wire
CompCare Receives NCQA Accreditation Approval for Recently Launched Puerto Rico Operations
[ Tue, Dec 14th 2010 ] - Market Wire
Health Net Joins National Campaign to Raise Aware .. ructive Pulmonary Disease (COPD) in the Workplace
[ Tue, Dec 14th 2010 ] - Market Wire
Electromed, Inc. CEO to Ring NASDAQ Closing Bell
[ Tue, Dec 14th 2010 ] - Market Wire
Varian-Equipped Proton Therapy Center Becomes Fir .. y-Modulated Proton Therapy (IMPT) Cancer Treatmen
[ Tue, Dec 14th 2010 ] - Market Wire
Hythiam Announces New Board Member, Kelly McCrann
[ Tue, Dec 14th 2010 ] - Market Wire
Zynex Expands International Business Initiative
[ Tue, Dec 14th 2010 ] - Market Wire
Compugen Announces Positive Therapeutic Effect of .. GEN-15001 in Animal Model of Rheumatoid Arthritis
[ Tue, Dec 14th 2010 ] - Market Wire
MEDNAX Announces the Acquisition of San Antonio Pediatric Hospitalist Practice
[ Tue, Dec 14th 2010 ] - Market Wire
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
[ Tue, Dec 14th 2010 ] - Market Wire
AngioDynamics to Report Fiscal 2011 Second Quarte .. sults and Hold Conference Call on January 4, 2011
Mon, December 13, 2010
[ Mon, Dec 13th 2010 ] - Market Wire
Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th
[ Mon, Dec 13th 2010 ] - Market Wire
Richard Snchez, M.D., Named Chief Medical Officer of Molina Healthcare of Utah
[ Mon, Dec 13th 2010 ] - Market Wire
Registration Period for North American Companies for the 2011 IR Global Rankings Starts Tomorrow
[ Mon, Dec 13th 2010 ] - Market Wire
Schiff Nutrition International, Inc. Announces Timing of Fiscal 2011 Second Quarter Results
[ Mon, Dec 13th 2010 ] - Market Wire
Baxtera?s Board of Directors Approves New Share Repurchase Authorization of $2.5 Billion
[ Mon, Dec 13th 2010 ] - Market Wire
Inhibitex Reports Promising Top-Line Results from .. II Trial of FV-100 for the Treatment of Shingles
[ Mon, Dec 13th 2010 ] - Market Wire
Lannett Announces Proposed Public Offering of Common Stock
[ Mon, Dec 13th 2010 ] - Market Wire
WellCare Partners with The Results Companies to Bring More Than 200 Jobs to Central Florida
[ Mon, Dec 13th 2010 ] - Market Wire
CIGNA Announces Appearance at the 2011 J.P. Morgan Healthcare Conference
[ Mon, Dec 13th 2010 ] - Market Wire
SurModics Comments on Announcement by Ramius
[ Mon, Dec 13th 2010 ] - Market Wire
BrainStorm Announces Resignation of CEO and Appoi .. al of Israel in New York, Ambassador Alon Pinkas,
[ Mon, Dec 13th 2010 ] - Market Wire
Sanofi-Aventis, Republic Services, Citigroup, American International and General Motors
[ Mon, Dec 13th 2010 ] - Market Wire
Alliance HealthCare Services Schedules Conference .. bcast to Review Full Year 2011 Financial Guidance
[ Mon, Dec 13th 2010 ] - Market Wire
Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST

Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST


Published on 2010-12-13 06:05:25 - Market Wire
  Print publication without navigation


BOTHELL, Wash.--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that management will present at the 2010 Deutsche Bank BioFEST conference on Tuesday, December 14, 2010, at 1:05 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Geneticsa™ website, [ www.seattlegenetics.com ], under the aInvestors and Newsa section.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company recently reported positive data from a pivotal Hodgkin lymphoma trial and phase II systemic anaplastic large cell lymphoma (ALCL) trial with its lead product candidate, brentuximab vedotin. Seattle Genetics plans to submit a Biologics License Application for brentuximab vedotin to the U.S. Food and Drug Administration for both relapsed or refractory Hodgkin lymphoma and ALCL in the first quarter of 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].

Contributing Sources